Blatant manipulation: overpricing essential medicines

Posted on


Othoman Mellouk, describes some tactics used by companies to hike drug prices. He also highlights how civil society is fighting back. Othoman is ITPC’s Intellectual Property & Access to Medicines Expert.
When I caught sight of the recent news that Germany’s patent court had granted a compulsory license for the manufacturing of a HIV drug, I celebrated.
A compulsory license is a legal tool at governments disposal (included in national laws and authorized by international agreements and treaties). It allows them to suspend patent protection on a specific medicine and authorize someone other than the patent owner to produce a generic version of a medicine to address a public health problem. It makes essential, expensive, medicines more affordable.
The scenario of over-priced drugs is so common, that you’d think compulsory licenses would be fairly standard. The case of Gilead charging between $4 and $1000 a day for the same medicine depending on the country it’s marketing to is well-known. Unfortunately, compulsory licenses are rarely used to address such abuses…
Read the full article on the Huffington Post blog here.